Compare KRP & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | OLMA |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2017 | 2020 |
| Metric | KRP | OLMA |
|---|---|---|
| Price | $15.26 | $9.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $17.33 | ★ $44.89 |
| AVG Volume (30 Days) | 827.3K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $333,830,000.00 | N/A |
| Revenue This Year | $6.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $11.31 | $3.90 |
| 52 Week High | $15.80 | $36.26 |
| Indicator | KRP | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 27.74 |
| Support Level | $14.10 | $7.79 |
| Resistance Level | $15.65 | $11.54 |
| Average True Range (ATR) | 0.33 | 0.78 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 65.25 | 8.46 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.